In the subgroup of patients with HER2-positive esophagogastric adenocarcinoma, the combination of standard-of-care perioperative FLOT therapy with trastuzumab reported a high pathological complete response (pCR) rate and similarly promising survival data. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.